Breaking News

  Something unusual happened in men's health this year. The evidence on testosterone got better and more complicated at the same time — and the combination undercuts both camps in the argument. If you've been following the "low T" conversation, here's where it actually stands. First, the reassurance The TRAVERSE trial randomized more than 5,200 men aged 45–80 with documented hypogonadism and elevated cardiovascular risk to testosterone gel or placebo, followed for a median of roughly 22 months. The primary outcome — cardiovascular death, heart attack or stroke — came in at 7.0% in the testosterone group, meeting non-inferiority. That settled a question that had hung over the field for a decade. In 2025, the FDA removed the boxed cardiovascular warning from testosterone labels, while adding a blood-pressure warning. For men with genuine, properly diagnosed hypogonadism, that's meaningful. Treatment that works, with the main cardiovascular fear addresse...

  Most men don't hit a wall. They drift. There's no diagnosis, no collapse, no single bad day that changes things. Just a gradual slide where a man who used to operate at full capacity settles into running at seventy percent — and after four or five years, forgets that seventy percent isn't the number. He still performs. He still provides. He just does all of it while tired, and calls that adulthood.   The arithmetic of the slide What's actually happening is mechanical, and understanding it removes most of the shame. Sleep erodes first — forty minutes at a time until six broken hours is the new normal. That matters more than it sounds, because the majority of a man's daily testosterone release happens during sleep. Cortisol climbs and doesn't come back down, because the stress has no end point to resolve at. Elevated cortisol drives fat to the abdomen specifically. And abdominal fat isn't inert storage — it contains aromatase , the enzyme that converts...